An Update on Common Pharmaceuticals in the Prevention of Pancreatic Cancer

In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2022-05, Vol.14 (5), p.e25496-e25496
Main Authors: Miyaki, Candace, Lynch, Launa M
Format: Article
Language:English
Subjects:
Adenosine
Antidiabetics
Beta blockers
Cancer therapies
Cohort analysis
Diabetes
Disease prevention
Endocrinology/Diabetes/Metabolism
Epidermal growth factor
Kinases
Medical prognosis
Meta-analysis
Obesity
Oncology
Pancreatic cancer
Pharmaceuticals
Preventive Medicine
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this review, we aim to update readers about the most recent studies on common pharmaceuticals and their association with pancreatic cancer risk. The use of prophylactic aspirin, metformin, beta-blockers, and statins has been studied in the past but showed inconclusive results in the reduction of pancreatic cancer incidence. However, in recent studies, these medications along with combination therapy of aspirin and metformin were found to have a more significant association with decreasing risk. Given the poor prognosis of pancreatic cancer despite treatment, medication prophylaxis prevention should be considered. In this review, we hope to encourage future case-control or prospective studies on common medications that have shown great potential in delaying pancreatic cancer development.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.25496